Autopsy report · NCT03613870

PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds

“Administratively closed prior enrollment of participants.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

The University of Texas Medical Branch, Galveston

Sponsor type

University, hospital or other

Conditions

Partial-thickness Burn

Interventions

PermeaDerm; Mepilex Ag

Participants

0

Trials that died the same way

• Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
  “The study closed prior to enrolling any participants.” (78% match in meaning)
• Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
  “Closed to accrual to allow enrollment on another more promising trial.” (76% match in meaning)
• Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
  “Study closed before total enrollment met.” (75% match in meaning)
• Reconstruction Flaps for Nasal Surgical Wounds RCT
  “Study closed before enrollment could begin.” (75% match in meaning)
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
  “Study closed to enrollment due to low accrual.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.